Inhibition of IRAK4 with a specific inhibitor in MYD88L256P mutant ABC-DLBCLs could prevent NF-κB signaling, and inhibited tumor growth when combined with ibrutinib [162]. The gene discussed is NFKB1; the disease is neoplasm.